all the information, none of the junk | biotech • healthcare • life sciences

At Verastem, Infinity’s Former Blood Cancer Drug Heads to FDA

Verastem has filed for FDA approval of duvelisib, a blood cancer drug the Needham, MA, company took a shot on in a 2016 bargain deal with Infinity Pharmaceuticals.

Verastem will seek approval of duvelisib as a treatment for patients who have one of three different blood cancers—chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, or follicular lymphoma—and haven’t responded to other treatment. Verastem hopes to begin selling the drug next year.